APGE

Apogee Therapeutics is a clinical-stage biotech developing antibody therapies for inflammatory and immunology indications, led by zumilokibart (APG777) plus APG279, APG273 and APG808. It has no product revenue and no approved products, so the investment case rests entirely on pipeline progress rather than current financials. FY2025 reflects a company in full development mode: net loss widened to -$256M, operating loss to -$286M, and R&D rose 27.9% to $215M as trials advanced. Operating cash burn was -$227M.

The one clear strength is the balance sheet. Per the MD&A, at December 31, 2025 Apogee held $131.5 million of cash and cash equivalents plus $598.6 million of marketable securities and additional long-term marketable securities (about $902.9 million of total cash and investments). Against ~$227M of annual operating cash burn, that provides multiple years of runway to reach key clinical readouts without immediate dilution — a meaningful advantage over thinly-capitalized peers. Total liabilities are trivial at $33.3M, so the enterprise is essentially unlevered and funded by equity.